David Meek

David Meek was appointed CEO soon after FerGene was created. He has over 30 years of biopharma experience commercializing and developing innovative medicines for patients across a range of therapeutic areas.

Before moving to FerGene, David was the Chief Executive Officer (CEO) and a Board Member of Ipsen where he was responsible for delivering industry-leading sales and shareholder growth of a global biopharma focused on oncology and specialty care. David has also held several executive leadership positions including Executive Vice President and President of Baxalta Oncology prior to its acquisition by Shire; CCO of Endocyte; Region Head, Novartis Oncology; CEO of Novartis Canada, and Global Franchise Head. He began his biopharma career at Johnson & Johnson and Janssen Pharmaceutica. David also serves on the board of directors for two publicly traded biotech companies, uniQure (QURE) and Entasis (ETTX). David has been active throughout his career to enhance the innovation agenda of the biopharma industry. He has previously served as an industry member of the board of directors of the Pharmaceutical Research Manufacturers of America (PhRMA), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the European Federation of Pharmaceutical Industry Association (EFPIA).

Prior to his biopharma career, David was a commissioned officer in the United States Army, where he was awarded the Bronze Star Medal.